68Ga-HA-DOTATATE

N/A

Report date: 2025/11/20 11:38:16

NME

Base Information

Drug Name68Ga-HA-DOTATATE

Drug Alias Name68Ga-DOTA-3-iodo-Tyr3-octreotate68Ga-DOTA-iodoTyr3-octreotate[68Ga]DOTA-3-iodo-Tyr3-octreotate[68Ga]high-affinity DOTATATE68Ga-HA-DOTATATE

ClassificationRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionSomatostatin receptor 2 modulators

TargetsSomatostatin receptor 2

Therapy Area/IndicationsNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Alberta

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Alberta

Inactive CompaniesN/A

Active IndicationsNeuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A